ArticleCirculation2022
SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism.
Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of anemia on clinical outcomes in patients with acute heart failure: A systematic review and meta-analysis.Clinical cardiology · 2024Pooled it
- Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies.Cardiovascular diabetology · 2023Pooled it
- Phosphorus Magnetic Resonance Spectroscopy (Medicina (Kaunas, Lithuania) · 2023Pooled it
- Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial.Diabetologia · 2026Trial
- Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects.Drug design, development and therapy · 2023Trial
- Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease.Journal of veterinary internal medicine · 2026Article
- Metabolic reprogramming in diabetes and other endocrine and metabolic disorders: exploring the Warburg effect, ketones, and SGLT2 inhibitors.Reviews in endocrine & metabolic disorders · 2026Review
- Cardiorenal protective effects of dapagliflozin combined with valsartan in patients with type 2 diabetes mellitus and hypertension: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study.Cardiovascular diabetology · 2025Observational
- Deletion of cardiac fibroblast growth factor-23 beneficially impacts myocardial energy metabolism in left ventricular hypertrophy.npj metabolic health and disease · 2025Article
- Multi-omics reveals the mechanism of vagus nerve stimulation in the treatment of chronic congestive heart failure.Scientific reports · 2025Article
- Comparison Between SGLT2 Inhibitors and Lactation: Implications for Cardiometabolic Health in Parous Women.Metabolic syndrome and related disorders · 2025Review
- Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.Cardiovascular drugs and therapy · 2025Article
- Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus.Cardiovascular diagnosis and therapy · 2024Article
- SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.Cardiovascular diabetology · 2024Review
- The Role of Short-Chain Fatty Acids in Myocardial Ischemia-Reperfusion Injury.Current nutrition reports · 2024Review
- SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling.Cardiovascular diabetology · 2024Article
- New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.Genes & diseases · 2024Review
- Article
- The Beneficial Effect of the SGLT2 Inhibitor Dapagliflozin in Alleviating Acute Myocardial Infarction-Induced Cardiomyocyte Injury by Increasing the Sirtuin Family SIRT1/SIRT3 and Cascade Signaling.International journal of molecular sciences · 2024Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
36095062What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.